Maze Therapeutics (MAZE) CMO Harold Bernstein Sells Shares

What Happened Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics (MAZE), sold a total of 10,295 shares of MAZE stock in transactions on September 2–3, 2026, disposing of approximately $270,111 worth of shares. The reported trades were open market/private sales: 4,481 shares at a weighted average $26.38 ($118,191), 625 shares at $27.12 ($16,951), 5,130 shares at $26.01 ($133,448), and 59 shares at $25.78 ($1,521). These sales were reported on a Form 4 filed 2026-09-04.

Key Details

• Transaction type: Sales (code S) on 2026-09-02 and 2026-09-03; Form 4 filed 2026-09-04. No late-filing flag indicated in the provided data.
• Total shares sold: 10,295; total proceeds disclosed: $270,111.
• Reported prices: several weighted averages; underlying trade ranges per filing:
  • One set ranged $26.03–$27.00 (weighted avg reported)
  • One set ranged $27.055–$27.40 (weighted avg reported)
  • One set ranged $25.743–$26.65 (weighted avg reported)
• Footnote: The filing states these transactions include shares sold to satisfy tax-withholding obligations from the vesting of restricted stock units (RSUs). The reporting person offers to provide a full breakdown of the number of shares sold at each separate price upon request to the company, shareholders, or the SEC staff.
• Shares owned after the transactions: not specified in the provided filing details.

Context These sales were reported as tax-withholding related to RSU vesting — a routine administrative disposition rather than a clear signal of insider sentiment. For retail investors, purchases by insiders often carry more forward-looking weight; routine tax sales are common and typically reflect vesting tax obligations rather than a judgment about the company's prospects.